Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis

Journal of the National Cancer Institute

Volumn 92, Issue 9, 2000, Pages 690-698

  Zur Hausen, Harald ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; REGULATOR PROTEIN; VIRUS DNA;

ANUS CARCINOMA; CANCER RISK; DISEASE ASSOCIATION; DNA DETERMINATION; HUMAN; NONHUMAN; OROPHARYNX CARCINOMA; PENIS CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; REVIEW; RISK ASSESSMENT; UTERINE CERVIX CARCINOMA; VIRUS CARCINOGENESIS; VIRUS CELL TRANSFORMATION; VIRUS STRAIN; VULVA CARCINOMA; WART VIRUS;

CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HUMANS; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS;

EID: 0034600355     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. de Villiers EM. Human pathogenic papillomavirus types: an update. Curr Top Microbiol Immunol 1994;186:1-12.
2. zur Hausen H. Papillomaviruses in human cancers. Proc Assoc Am Physicians 1999;111:1-7.
3. Scheffner M, Romanczuk H, Munger K, Huibregtse JM, Mietz JA, Howley PM. Functions of human papillomavirus proteins. Curr Top Microbiol Immunol 1994;186:83-96.
4. Howley PM. Papillomavirinae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. Philadelphia (PA): Lippincott-Raven; 1996. p. 2045-76.
5. zur Hausen H. Genital papillomavirus infections. In: Rigby PW, Wilkie NM, editors. Viruses and cancer. Cambridge (U.K.): Cambridge University Press; 1986. p. 83-90.
6. Schwarz, E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985;314:111-4.
7. Burkhardt A, Willingham M, Gay C, Jeang KT, Schlegel R. The E5 oncoprotein of bovine papillomavirus is oriented asymmetrically in Golgi and plasma membranes. Virology 1989;170:334-9.
8. Hwang ES, Nottoli T, DiMaio D. The HPV 16 E5 protein: expression, detection, and stable complex formation with transmembrane proteins in COS cells. Virology 1995;211:227-33.
9. Conrad M, Bubb VJ, Schlegel R. The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J Virol 1993;67:6170-8.
10. Finbow ME, Pitts JD. Is the gap junction channel - hte connexon - made of connexin or ductin? J Cell Sci 1993;106:463-71.
11. Gu Z, Matlashewski G. Effect of human papillomavirus type 16 oncogenes on MAP kinase activity. J Virol 1995;69:8051-6.
12. Crusius K, Auvinen E, Alonso A. Enhancement of EGF-and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Oncogene 1997;15:1437-44.
13. Tsao YP, Li LY, Tsai TC, Chen SL. Human papillomavirus type 11 and 16 E5 represses p21(WAF-1/SDI 1/CIP-1) gene expression in fibroblasts and keratinocytes. J Virol 1996; 70:7535-9.
14. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV 16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989;8: 3905-10.
15. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of human papillomavirus type 16 are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63:4417-23.
16. McDougall JK. Immortalization and transformation of human cells by human papillomavirus. Curr Top Microbiol Immunol 1994; 186:101-19.
17. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248: 76-9.
18. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505.
19. White AE, Livanos EM, Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 1994;8:666-77.
20. Reznikoff CA, Belair C, Savelieva E, Zhai Y, Pfeifer K, Yeager T, et al. Long-term genome stability and minimal genotypic bind phenotypic alterations in HPV16 E7-, but not E6-immortalized human uroepithelial cells. Genes Dev 1994;8:2227-40.
21. Havre PA, Yuan J, Hedrick L, Cho KR, Glazer PM. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res 1995;55:4420-4.
22. Kessis TD, Conolly DC, Hedrick L, Cho KR. Expression of HPV16 E6 or E7 increases integration of foreign DNA. Oncogene 1996;13:427-31.
23. Kiyono T, Foster SA, Koop I, McDougall JK, Galloway DA, Klingelhutz AJ. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998;396:84-8.
24. Oda H, Kumar S, Howley PM. Regulation of the Src family tyrosine kinase BIk through E6AP-mediated ubiquitination. Proc Natl Acad Sci U S A 1999;96:9557-62.
25. Chen JJ, Reid CE, Band V, Androphy EJ. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science 1995; 269:529-31.
26. Tong X, Howley PM. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proc Natl Acad Sci U S A 1997;94:4412-7.
27. Vande Pol SB, Brown MC, Turner CE. Association of bovine papillomavirus type 1 E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein interaction motif. Oncogene 1998;16:43-52.
28. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, Ishibashi M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997;94:11612-6.
29. Gao Q, Srinivasan S, Boyer SN, Wazer DE, Band V. The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein. E6TP1, and target it for degradation. Mol Cell Biol 1999;19:733-44.
30. Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998;12:2061-72.
31. Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettil JA, Stadler WM. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6. but not in E7, transformed human uroepithelial cells. Cancer Res 1996;56:2886-90.
32. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-8.
33. Xiong Y, Kuppuswamy D, Li Y, Livanos EM, Hixon M, White A, et al. Alteration of cell cycle kinase complexes in human papillomavirus E6-and E7-expressing fibroblasts precedes neoplastic transformation. J Virol 1996;70:999-1008.
34. Thomas M, Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998;10:2943-54.
35. Thomas M, Banks L. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J Gen Virol 1999;80:1513-7.
36. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996;380: 79-82.
37. Steenbergen RD, Walboomers JM, Meijer CJ, van der Raaij-Helmer EM, Parker JN, Chow LT, et al. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele loss at 3p, 10p, 11q and /or 18q. Oncogene 1996;13:1249-57.
38. Mavromatis KO, Jones DL, Mukherjee R, Yee C, Grace M, Munger K. The carboxyl-terminal zinc-binding domain of the human papillomavirus E7 protein can be functionally replaced by homologous sequences of the E6 protein. Virus Res 1997;52:109-18.
39. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
40. Dyson N, Guida P, Munger K, Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 1992;66: 6893-902.
41. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996;56:4620-4.
42. Bagchi S, Raychaudhuri P, Nevins JR. Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for E1A trans-activation. Cell 1990;62:659-69.
43. Bandara LR, Adamczewski JP, Hunt T, La Thangue NB. Cyclin A and the retinoblastoma gene product complex with a common transcription factor. Nature 1991;352:249-51.
44. Jewers RJ, Hildebrandt P, Ludlow JW, Kell B, McCance DJ. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J Virol 1992;66:1329-35.
45. Brehm A, Nielsen SJ, Miska EA, McCance DJ, Reid JL, Bannister AJ, el al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 1999;18:2449-58.
46. Davies R, Hicks R, Crook T, Morris J, Vousden K. Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. J Virol 1993;67:2521-8.
47. 2pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci U S A 1999; 96:1291-6.
48. Schilling B, De-Medina T, Syken J, Vidai M, Munger K. A novel human DnaJ protein, hTid-1, a homolog of the Drosophila tumor suppressor protein Tid56. can interact with the human papillomavirus type 16 E7 oncoprotein. Virology 1998;247:74-85.
49. Berezutskaya E, Bagchi S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J Biol Chem 1997;272:30135-40.
50. McIntyre MC, Ruesch MN, Laimins LA. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology 1996;215:73-82.
51. Arroyo M, Bagchi S, Raychaudhuri P. Association of human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex. Mol Cell Biol 1993;13:6537-46.
52. Zerfass K, Schulze A, Spitkovsky D, Friedman V, Henglein B, Jansen-Durr P. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J Virol 1995;69:6389-99.
53. Antinore MJ, Birrer MJ, Patel D, Nader L, McCance DJ. The human papillomavirus type 16 E7 gene product interacts with and transactivates the AP1 family of transcription factors. EMBO J 1996;15: 1950-60.
54. Nead MA, Baglia LA, Antinore MJ, Ludlow JW, McCance DJ. Rb binds c-Jun and activates transcription. EMBO J 1998;17:2342-52.
55. Massimi P, Pim D, Banks L. Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity. J Gen Virol 1997;78: 2607-13.
56. Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV 16 E7 oncoprotein. Genes Dev 1997;11:2090-100.
57. Jones DL, Alani RM, Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 1997;11:2101-11.
58. Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R. Botz JW, Jansen-Durr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996;13:2323-30.
59. Puthenveettil JA, Frederickson SM, Reznikoff CA. Apoptosis in human papillomavirus 16 E7-, but not in E6-immortalized human uroepithelial cells. Oncogene 1996;13:1123-31.
60. Iglesias M, Yen K, Gaiotti D, Hildesheim A, Stoler MH, Woodworth CD. Human papillomavirus type 16 E7 protein sensitizes cervical keratinocytes to apoptosis and release of interleukin-1 alpha. Oncogene 1998;17: 1195-205.
61. Stoppler H, Stoppler MC, Johnson E, Simbulan-Rosenthal CM, Smulson ME, Iyer S, et al. The E7 protein of human papillomavirus type 16 sensitizes primary human keratinocytes to apoptosis. Oncogene 1998;17: 1207-14.
62. Magal SS, Jackman A, Pei XF, Schlegel R, Sherman L. Induction of apoptosis in human keratinocytes containing mutated p53 alleles and its inhibition by both the E6 and E7 oncoproteins. Int J Cancer 1998;75: 96-104.
63. Demers GW, Foster SA, Halbert CL, Galloway DA. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci U S A 1994;91:4382-6.
64. Barnard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999;259: 305-13.
65. Liu X, Han S, Baluda MA, Park NH. HPV-16 oncogenes E6 and E7 are mutagenic in normal human keratinocytes. Oncogene 1997;14: 2347-53.
66. Martin LG, Demers GW, Galloway DA. Disruption of the G1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E. J Virol 1998;72:975-85.
67. Firzlaff JM, Galloway DA, Eisenman RN, Luscher B. The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biol 1989;1:44-53.
68. Massimi P, Pim D, Storey A, Banks L. HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Oncogene 1996;12:2325-30.
69. Stoppler H, Hartmann DP, Sherman L, Schlegel R. The human papillomavirus type 16 E6 and E7 oncoproteins dissociate cellular telomerase activity from the maintenance of telomere length. J Biol Chem 1997;272: 13332-7.
70. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1996;1288:F55-78.
71. Pereira-Smith OM, Smith JR. Expression of SV40 T antigen in finite lifespan hybrids of normal and SV40-transformed fibroblasts. Somatic Cell Genet 1981;7:411-21.
72. Pereira-Smith OM, Smith JR. Genetic analysis of indefinite division in human cells: identification of four complementation groups. Proc Natl Acad Sci U S A 1988;85:6042-6.
73. Whitaker NJ, Kidston EL, Reddel RR. Finite lifespan of hybrids formed by fusion of different simian virus 40-immortalized human cell lines. J Virol 1992;66:1202-6.
74. Chen TM, Pecoraro G, Defendi V. Genetic analysis of in vitro progression of human papillomavirus-transfected human cervical cells. Cancer Res 1993;53:1167-71.
75. Crook T, Storey A, Almond N, Osborn K, Crawford L. Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in the hormone-dependent transformation of primary mouse cells. Proc Natl Acad Sci U S A 1988;85:8820-4.
76. Storey A, Massimi P, Dawson K, Banks L. Conditional immortalization of primary cells by human papillomavirus type 18 E6 and EJ-ras defines an E6 activity in G0/G1 phase which can be substituted for mutations in p53. Oncogene 1995;11:653-61.
77. von Knebel Doeberitz M, Rittmuller C, Aengeneyndt F, Jansen-Durr P, Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions. J Virol 1994;68:2811-21.
78. von Knebel Doeberitz M, Rittmuller C, Zur Hausen H, Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 antisense RNA [letter]. Int J Cancer 1992;51:831-4.
79. Watanabe S, Kanda T, Yoshiike K. Growth dependence of human papillomavirus 16 DNA-positive cervical cancer cell lines and human papillomavirus 16-transformed human and rat cells on the viral oncoproteins. Jpn J Cancer Res 1993;84:1043-9.
80. Hu G, Liu W. Hanania EG, Fu S, Wang T, Deisseroth AB. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells. Cancer Gene Ther 1995;2:19-32.
81. Venturini F, Braspenning J, Homann M, Gissmann L, Sczakiel G. Kinetic selection of HPV 16 E6/E7-directed antisense nucleic acids: antiproliferative effects on HPV 16-transformed cells. Nucleic Acids Res 1999;27:585-92.
82. Storey A, Oates D, Banks L, Crawford L, Crook T. Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res 1991; 19:4109-14.
83. Tan TM, Ting RC. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res 1995;55:4599-605.
84. Chen Z, Kamath P, Zhang S, Weil MM, Shillitoe EJ. Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18. Cancer Gene Ther 1995;2:263-71.
85. Seagon S, Durst, M. Genetic analysis of an in vitro model system for human papillomavirus type 16-associated tumorigenesis. Cancer Res 1994;54:5593-8.
86. Ku JL, Kim WH, Park HS, Kang SB, Park JG. Establishment and characterization of 12 uterine cervical carcinoma cell lines: common sequence variation in the E7 gene of HPV-16-positive cell lines. Int J Cancer 1997; 72:313-20.
87. Kersemaekers AM, Kenter GG, Hermans J, Fleuren GJ, van de Vijver MJ. Allelic loss and prognosis in carcinoma of the uterine cervix. Int J Cancer 1998;79:411-7.
88. Le Beau MM. Chromosomal fragile sites and cancer-specific rearrangements. Blood 1986;67:849-58.
89. Druck T, Berk L, Huebner K. FHITness and cancer. Oncol Res 1998;10: 341-5.
90. Magnusson PK, Sparen P, Gyllensten UB. Genetic link to cervical tumours. Nature 1999;400:29-30.
91. Storey A, Thomas M, Kalita A, Harwood C. Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
92. Josefsson AM, Magnusson PK, Ylitalo N. Quarforth-Tubbin P. Ponten J, Adami HO, et al. p53 polymorphism and risk of cervical cancer [letter]. Nature 1998;396:531; discussion 532.
93. zur Hausen H. Cell-virus gene balance hypothesis of carcinogenesis. Behring Inst Mitt 1977;61:23-30.
94. zur Hausen H. Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet 1986;2:489-91.
95. Bartsch D, Boye B, Baust C, zur Hausen H, Schwarz E. Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor β gene in non-tumorigenic and tumorigenic HeLa hybrid cells. EMBO J 1992;11: 2283-91.
96. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, et al. 13-cis-Retinoic acid plus interferon α-2a: highly active systemic therapy for squamous cell carcinomas of the cervix. J Natl Cancer Inst 1992;84:241-5.
97. Iglesias M, Plowman GD, Woodworth CD. Interleukin-6 and interleukin-6 soluble receptor regulate proliferation of normal, human papillomavirus-immortalized, and carcinoma-derived cervical cells in vitro. Am J Pathol 1995;146:944-53.
98. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999;59:3698-704.
99. Braun L, Durst M, Mikumo R, Gruppuso P. Differential response of nontumorigenic human papillomavirus type 16-positive epithelial cells to transforming growth factor beta 1. Cancer Res 1990;50:7324-32.
100. Woodworth CD, Notario V, DiPaolo JA. Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells. J Virol 1990;64:4767-75.
101. De Geest K, Bergman CA, Turyk ME, Frank BS, Wilbanks GD. Differential response of cervical intraepithelial and cervical carcinoma cell lines to transforming growth factor-beta I. Gynecol Oncol 1994;55:376-85.
102. Woodworth CD, Lichti U, Simpson S, Evans CH, DiPaolo JA. Leukoregulin and γ-interferon inhibit human papilloma virus type 16 gene transcription in human papillomavirus-immortalized human cervical cells. Cancer Res 1992;52:456-63.
103. Kyo S, Inoue M, Hayasaka N, Inoue T, Yutsudo M, Tanizawa O, et al. Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines. Virology 1994;200:130-9.
104. Malejczyk J, Malejczyk M. Breitburd F, Majewski S, Schwarz A, Expert-Besancon N, et al. Progressive growth of human papillomavirus type 16-transformed keratinocytes is associated with an increased release of soluble tumour necrosis factor (TNF) receptor. Br J Cancer 1996;74: 234-9.
105. Bornstein J, Lahat N, Kinarty A. Revel M, Abramovici H, Shapiro S. Interferon-beta and -gamma, but not tumor necrosis factor-alpha, demonstrate immunoregulatory effects on carcinoma cell lines infected with human papillomavirus. Cancer 1997;79:924-34.
106. Jacobs AJ, Dawoud L, Kovacs Z, Ratliff TL. Inhibition of proliferation of lines derived from human cervical carcinomas by cytotoxic drugs and by recombinant interferons. Gynecol Oncol 1989;32:31-6.
107. Khan MA, Tolleson WH, Gangemi JD, Pirisi L. Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons. J Virol 1993;67:3396-403.
108. Bosch FX, Schwarz E, Boukamp P, Fusenig NE, Bartsch D, zur Hausen H. Suppression in vivo of human papillomavirus type 18 E6-E7 gene expression in nontumorigenic HeLa X fibroblast hybrid cells. J Virol 1990;64:4743-54.
109. Durst M, Bosch FX, Glitz D, Schneider A, zur Hausen H. Inverse relationship between human papillomavirus (HPV) type 16 early gene expression and cell differentiation in nude mouse epithelial cysts and tumors induced by HPV-positive human cell lines. J Virol 1991;65:796-804.
110. Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992;23:117-28.
111. Rosl F, Lengert M, Albrecht J, Kleine K, Zawatzky R, Schraven B, zur Hausen H. Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids. J Virol 1994;68:2142-50.
112. Soto U, Das BC, Lengert M, Finzer FP, zur Hausen H, Rosi F. Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-α mediated repression of viral transcription and modification of the AP-1 transcription complex. Oncogene 1999;18: 3187-98.
113. Kyo S, Klumpp DF, Inoue M, KanayaT, Laimins LA. Expression of AP1 during cellular differentiation determines human papillomavirus E6/E7 expression in stratified epithelial cells. J Gen Virol 1997;78(Pt 2):401-11.
114. Pei XF, Meek JM, Greenhalgh D, Schlegel R. Cotransfection of HPV-18 and v-fos DNA induces tumorigenicity of primary human keratinocytes. Virology 1993;196:855-60.
115. Medina-Martinez O, Vallejo V, Guido MC, Garcia-Cananca A. Ha-ras oncogene-induced transcription of human papillomavirus type 18 E6 and E7 oncogenes. Mol Carcinog 1997;19:83-90.
116. Saez E, Rutberg SE, Mueller E, Oppenheim H, Smoluk J, Yuspa SH, et al. c-fos is required for malignant progression of skin tumors. Cell 1995; 82:721-32.
117. Li JJ, Rhim JS, Schlegel R, Vousden KH, Colburn NH. Expression of dominant negative jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene 1998;16:2711-21.
118. Bergers G, Graninger P, Braselmann S, Wrighton C, Busslinger M. Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron. Mol Cell Biol 1995;15:3748-58.
119. Kaiser A, Brembeck FH, von Marschall Z, Riecken EO, Wiedenmann B, Rosewicz, S. Fra-1: a novel target for retinoid action. FEBS Lett 1999; 448:45-8.
120. Smits PH, Smits RP, Minnaar BA, Hemmings RE, Mayer-Jaekel R, Schuurman RJ, et al. The 55 kDa regulatory subunit of protein phosphatase 2A plays a role in the activation of the HPV16 long control region in human cells with a deletion in the short arm of chromosome 11. EMBO J 1992;11:4601-6.
121. Munger K, Phelps WC. The human papillomavirus E7 protein as a transforming and transactivating factor. Biochim Biophys Acta 1993;1155: 111-23.
122. Band V, Zajchowski D, Kulesa V, Sager R. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci U S A 1990;87:463-7.
123. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991;184:9-13.